Predicting Melphalan Resistance in B-Cell Cancer
Author Information
Author(s): Boegsted Martin, Holst Johanne M., Fogd Kirsten, Falgreen Steffen, Sørensen Suzette, Schmitz Alexander, Bukh Anne, Johnsen Hans E., Nyegaard Mette, Dybkaer Karen
Primary Institution: Aalborg Hospital Science and Innovation Center, Aarhus University Hospital, Aalborg, Denmark
Hypothesis
Melphalan screens and gene expression profiles of B-cell cancer cell lines combined with multivariate statistics may provide predictive clinical information.
Conclusion
The study presents a melphalan resistance index generated from B-cell cancer cell lines, which needs further validation against known biomarkers.
Supporting Evidence
- The B-cell panel was able to predict a significantly higher risk of relapse and death with increasing resistance index.
- The most sensitive and resistant cell lines had high leverage, indicating their genes have important predictive value.
- The study utilized a combination of drug screens and gene expression profiles to develop a predictive model.
Takeaway
Researchers created a way to predict how well a cancer might respond to a drug called melphalan by studying different cancer cell lines in the lab.
Methodology
The study used microarray-based gene expression profiles and melphalan growth inhibition screens on 59 cancer cell lines, applying statistical analyses to build resistance signatures.
Limitations
The resistance index requires functional validation and correlation with known biomarkers in independent datasets.
Participant Demographics
The study involved 565 patients diagnosed with multiple myeloma and 87 patients with diffuse large B-cell lymphoma.
Statistical Information
P-Value
p<0.001
Confidence Interval
[2.41: 3.35]
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website